MA-NUMARES
Leading NMR diagnostics company numares AG today announced that the company made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for its AXINON® IVD System , a NMR-platform for AI-driven, metabolomics-based diagnostics. If cleared, AXINON® would become the first NMR-based clinical laboratory system using AI-evaluated metabolic data. Several multi-marker assays for AXINON® will cover numerous unmet medical needs, in order to prevent, diagnose and treat disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005057/en/
The clearance of AXINON® would bring a novel diagnostic approach to clinical laboratories, the combination of several metabolic biomarkers, so-called metabolite constellations, analyzed by advanced nuclear magnetic resonance (NMR) technology and evaluated by numares’ proprietary, AI-driven AXINON® diagnostic software.
"This U.S. regulatory filing for its diagnostics platform is an important milestone for numares ," said Winton Gibbons, President - US and co-Chief Executive Officer of numares . “After entering into collaborations on joint diagnostics development with analytical instrumentation and solution provider Bruker Corporation in January 2021, and with Mayo Clinic Laboratories in 2019, this FDA submission is the first step in our common endeavor to bring NMR diagnostics into routine clinical use, and make metabolomics-based diagnostics accessible to the patients.”
numares is currently developing multi-marker algorithms for several diagnostic tests on the AXINON® IVD System . These include AXINON® GFRNMR to reliably assess kidney function by improved determination of glomerular filtration rate (GFR). numares expects to submit this test to the FDA also in the first half 2021. The third assay AXINON® renalTX-SCORE® is intended to reliably identify early kidney rejection in post-transplant surveillance, and be submitted to the FDA in 2022. Further multi-marker tests are in development, e.g., for liver disease, cancer detection, and multiple sclerosis.
Dr. Maulik Shah, numares’ Medical Director comments: “AXINON® provides clinical laboratories with a powerful technology that leverages the information-rich metabolome with artificial intelligence to give healthcare professionals new insights into disease diagnosis and management for improved patient outcomes. At the same time, automation capabilities, excellent precision, easy operability will allow easy adaption of the FDA-cleared system by clinical laboratories and will make AXINON® an indispensable routine diagnostic tool in precision medicine.”
“The 510(k) submission of our AXINON® System is an important step and prerequisite to further strengthen commercialization of numares’ products in the United States”, concludes Dr. Volker Pfahlert, co-CEO of numares and chairman of the executive board. “Metabolic disorders are a rapidly increasing problem and major challenge to today’s healthcare systems. Patients will benefit from our approach to consider the patient's metabolome with sophisticated algorithms. Once cleared by the FDA, we believe AXINON® has the potential to meaningfully improve health outcomes and quality of life for millions of patients.”
The AXINON® System consists of AI-based AXINON® Software , ready-to-use AXINON® kits, and an advanced NMR technology, refined by numares’ proprietary Magnetic Group SignalingTM to ensure highly standardized and automated processing of serum or urine samples in high-throughput.
About numares
numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON® System employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. Magnetic Group Signaling (MGS® ) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005057/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Announces Appointment of Brett Icahn and Richard Mulligan to Board of Directors22.10.2025 22:15:00 CEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Brett Icahn and Richard Mulligan, Ph.D., to its board of directors, effective Oct. 20. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022380951/en/ Brett Icahn (Photo: IFF) These appointments follow the company’s previously disclosed cooperation agreement with Icahn Capital LP and its affiliates. Icahn serves as the Icahn designee to the IFF board, replacing Vincent Intrieri, and Mulligan joined as the mutually agreed independent director, replacing Margarita Paláu-Hernández. Intrieri and Paláu-Hernández stepped down from the board on Oct. 20. Icahn has been named to the Board’s Audit Committee and Transaction Committee, and Mulligan has been named to the Board’s Innovation Committee. “We are very pleased to welcome Brett and Richard to the IFF board,” said Kevin O’Byrne, chair of the IFF boa
OpenAI, Oracle and Vantage Data Centers Announce Stargate Data Center Site in Wisconsin22.10.2025 22:05:00 CEST | Press release
Vantage’s $15B+ investment in Port Washington represents the future of sustainable digital infrastructure with zero-emission energy resources, water-positive operations and billions in regional economic growth OpenAI, Oracle and Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced plans to develop a data center campus outside Milwaukee in Port Washington, Wisconsin. The new campus is part of OpenAI and Oracle’s previously announced partnership to invest up to 4.5 gigawatts of additional Stargate capacity and is the Midwest site that was recently announced as part of OpenAI’s Stargate expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022873578/en/ Vantage Data Centers’ $15B+ campus in Port Washington, Wisconsin represents the future of sustainable digital infrastructure. The campus will feature four cutting-edge data centers providing close to a gigawatt of AI capacity
Pure Lithium Opens New Chicago Headquarters, Advancing Commercialization of Its Lithium Metal Battery22.10.2025 19:24:00 CEST | Press release
Pure Lithium Corp., a disruptive vertically integrated lithium metal battery technology company, officially opened its new headquarters in Chicago’s Fulton Market district with a ribbon cutting ceremony Tuesday attended by community and business leaders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022239586/en/ From left: Ken Hoffman, Pure Lithium Special Advisor; Dr. Yuan Gao, Member of Pure Lithium Scientific Advisory Board; Derek Willis, Vice President of Commercial Development at Oxy Low Carbon Ventures and Pure Lithium Board Director; Miss Illinois Nitsaniyah Fitch; Chicago Mayor Brandon Johnson; Pure Lithium Founder, Chairman & CEO Emilie Bodoin; Illinois State Senator Lakesia Collins; Former Massachusetts Governor & Pure Lithium Board Director William F. Weld; Lisa Clemmons-Stott, Senior Economic Advisor, Director’s Office, Illinois Department of Commerce and Economic Opportunity The opening marks a milestone in
Doha Debates Launches New Debate Season with Al Jazeera22.10.2025 19:07:00 CEST | Press release
The new season brings global voices together for truth-seeking discussions Qatar Foundation’s Doha Debates launched a new season of its flagship program, Doha Debates, on October 21, co-produced with Al Jazeera Digital. The upcoming season features high-profile guests, bold global themes and a renewed focus on open, truth-seeking dialogue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022828303/en/ Qatar Foundation’s Doha Debates launches new debate season, bringing global voices together for truth-seeking discussions. (photo: AETOSWire) Airing weekly on Tuesdays through December 9, the eight-episode season explores three overarching themes—freedom, grand narratives and family. Each episode features leading thinkers and young changemakers engaging in timely conversations on the issues shaping humanity, ranging from meritocracy to social media; from love to architecture; from ancient traditions to the future of work. The
Picsart, Gen Z’s Preferred Digital Content Creation Platform, Takes LinkedIn Creators to Dracula’s Castle for “Why Your Marketing Sucks” Halloween Campaign22.10.2025 18:23:00 CEST | Press release
Picsart, the world’s leading digital creation platform, has announced the release of its new Halloween campaign and ebook, Why Your Marketing Sucks: a highly visual, tongue-in-cheek guide to the scariest mistakes marketers make and how to avoid them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022722043/en/ Why Your Marketing Sucks Ebook by Picsart The campaign, running from October 15 through October 31, combines horror-themed storytelling with practical marketing advice and expertise. Its centerpiece, the Why Your Marketing Sucks ebook, was co-created by Picsart and five top LinkedIn marketing influencers during an exclusive brand trip to Transylvania to visit Bran Castle — thought to be the home of Count Dracula himself. Picsart’s COO and Co-Founder, Mikayel Vardanyan, said “Gen Z represents more than 25% of today’s workforce. Picsart has been supporting this demographic for 15 years — more than half of our users ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom